



EPI-00671b

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jonathan W. Nyce

Appl. Ref. No: EPI-00671b

Serial No: 09/543,679

Group Art Unit: 1635

Filed: April 4, 2000

Examiner: Janet Epps, Ph.D.

Title: **LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE, COMPOSITIONS,  
KIT & METHOD FOR TREATMENT OF AIRWAY DISORDERS ASSOCIATED  
WITH BRONCHOCONSTRICITION, LUNG INFLAMMATION, ALLERGY(IES)  
& SURFACTANT DEPLETION**

INFORMATION DISCLOSURE STATEMENT**RECEIVED**

Assistant Commissioner for Patents  
Washington D. C. 20231

MAR 05 2002

Sir\Madam:

TECH CENTER 1600/2900

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the examiner is requested to make of record the enclosed European Supplementary Search Report of January 17, 2002 and the references cited therein, which are listed on the PTO 1449 submitted herewith. A copy of each of the listed references is also enclosed. An Information Disclosure Statement has previously been submitted and considered by the examiner in this case.

Although the information submitted herewith may be "material" to the examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention. Moreover, in accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

No fee is believed due for the submission of the IDS, however, the Assistant Commissioner for Patents is hereby authorized to charge the necessary fee to PTO Deposit Account No. **50-1728**.

Respectfully submitted.

EpiGenesis Pharmaceuticals, Inc.

Viviana Amzel, Ph.D.

Reg. No. 30,930

Attorney for Applicant

21  
February 19, 2002  
Date  
7 Clarke Drive  
Cranbury, NJ 08512  
Phone 609-409-3035  
Fax 609-860-8069  
Email VAmzel@epigene.com

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents Washington, D.C. 20231, on February 19, 2002, by Katsunori Ebata.

Signature

RECEIVED

MAR 05 2001

## TECH CENTER 1600/2900

SHEET 1 OF 1



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. EPI-00671b	SERIAL NO. 09/543,679
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	APPLICANT Jonathan W. Nyce	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE April 4, 2000	GROUP 1635

FOREIGN PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES	NO										
		9	6	4	0	1	6	2	12/19/96	WO	A61K	31/70	
		9	3	1	0	8	2	0	06/10/93	WO	A61K	48/00	
		9	8	1	1	2	1	1	03/19/98	WO	C12N	15/11	
		9	4	0	2	6	0	5	02/03/94	WO	C12N	15/12	
		9	8	2	3	2	9	4	06/04/98	WO	A61K	48/00	
		9	6	4	0	2	6	6	12/19/96	WO	A61K	48/00	
		9	3	1	2	7	5	6	07/08/93	WO	A61K		
		9	9	6	0	1	6	6	11/25/99	WO	C12Q	1/68	
		0	0	0	9	5	2	5	02/24/00	WO	C07H		

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	<p>Rahman, M. Sayeedur, et al., "Nebularine (9-2'-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenosine in vivo and in vitro", Mutation Research, vol. 377, no. 2, 1997, pages 263-268</p> <p>Loakes, D. et al., "5-Nitroindole as an universal base analogue", Nucleic Acids Research, vol. 22, no. 20, 1994, pages 4039-4043</p>
	<p>Ohtsuka, E. et al., "An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions", Journal of Biological Chemistry, vol. 260, no. 5, 10 March 1985 (1985-03-10), pages 2605-2608</p> <p>Nichols, R. et al., "A universal nucleoside for use at ambiguous sites in DNA primers", NATURE, vol. 369, no. 6480, 9 June 1994 (1994-06-09), pages 492-493</p>
	<p>Metzger W. James et al., "Oligonucleotide therapy of allergic asthma", Journal of Allergy and Clinical Immunology, vol. 104, no. 2 part 1, August 1999 (1999-08), pages 260-266</p>

EXAMINER	DATE CONSIDERED
----------	-----------------

**\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.**